Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers.
Target Price
The average target price of ECOR is 19.5 and suggests 209% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre